These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8309863)

  • 1. Lipoproteins and apolipoproteins. Making use of their metabolic properties to individualize therapy.
    Kottke BA
    Postgrad Med; 1994 Feb; 95(2):51-3, 57-8, 63-5. PubMed ID: 8309863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of hyperlipoproteinemia by plasma exchange].
    Homma Y
    Nihon Rinsho; 1992 Jan; 50 Suppl():370-3. PubMed ID: 1578709
    [No Abstract]   [Full Text] [Related]  

  • 3. [Primary hyperlipoproteinemias. Clinical, biological and physiopathological aspects].
    Bakir R; Chanu B; Rouffy J
    Pathol Biol (Paris); 1983 Apr; 31(4):248-58. PubMed ID: 6346238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Initial experiences with the effect of chronic intermittent electromyostimulation in patients with hyperlipoproteinemias and arterial circulatory disorders].
    Kuklinski B; Gibas P; Köhler H; Grossmann KD; Rühlmann C; Zimmermann R; Voigt H; Reuter W; Duck HJ; Bühnert G
    Z Gesamte Inn Med; 1988 Jan; 43(1):6-11. PubMed ID: 3258458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eicosanoids, apolipoproteins, lipoprotein particles, and atherosclerosis. Proceedings of the Fourth International Colloquium. March 17-19, 1988, Brussels, Belgium.
    Adv Exp Med Biol; 1988; 243():1-362. PubMed ID: 3223414
    [No Abstract]   [Full Text] [Related]  

  • 6. Formation of apolipoprotein-specific high-density lipoprotein particles from lipid-free apolipoproteins A-I and A-II.
    Clay MA; Cehic DA; Pyle DH; Rye KA; Barter PJ
    Biochem J; 1999 Feb; 337 ( Pt 3)(Pt 3):445-51. PubMed ID: 9895287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypercholesterolemia: genetic, dietary, and pharmacologic interrelationships.
    Levy RI
    Prog Clin Biol Res; 1981; 67():351-60. PubMed ID: 7029563
    [No Abstract]   [Full Text] [Related]  

  • 8. The inflammation: lipoprotein cycle.
    Barter P
    Atheroscler Suppl; 2005 May; 6(2):15-20. PubMed ID: 15823492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Most recent state of therapy of various forms of hyperlipoproteinemia].
    Widhalm K
    Vasa Suppl; 1990; 30():14-5. PubMed ID: 2075566
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
    Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
    Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genetic studies in familial hyperlipoproteinemia, and therapeutic implications].
    de Gennes JL
    Ann Biol Clin (Paris); 1988; 46(1):1-3. PubMed ID: 3389574
    [No Abstract]   [Full Text] [Related]  

  • 12. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?
    Battula SB; Fitzsimons O; Moreno S; Owens D; Collins P; Johnson A; Tomkin GH
    Metabolism; 2000 Aug; 49(8):1049-54. PubMed ID: 10954025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis.
    Wolfrum C; Poy MN; Stoffel M
    Nat Med; 2005 Apr; 11(4):418-22. PubMed ID: 15793583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoproteins modulate the inflammatory response to lipopolysaccharide.
    Berbée JF; Havekes LM; Rensen PC
    J Endotoxin Res; 2005; 11(2):97-103. PubMed ID: 15949136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biochemical diagnosis of hereditary hyperlipoproteinemias].
    Tvorogova MG; Rozhkova TA; Alidzhanova KhG; Semenova OA; Sobolev AV; Kukharchuk VV; Titov VN
    Ter Arkh; 1998; 70(4):9-15. PubMed ID: 9612894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of hyperlipoproteinemia].
    Drexel H; Follath F
    Schweiz Rundsch Med Prax; 1993 Apr; 82(17):506-9. PubMed ID: 8493437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoproteins: significance for lipid metabolism and for diagnosis of atherosclerotic disease.
    Kostner GM; Wurm H; Zechner R; Pilger E; Dieplinger H
    Prog Clin Biol Res; 1985; 188():67-77. PubMed ID: 4059260
    [No Abstract]   [Full Text] [Related]  

  • 19. [Lipoprotein metabolism].
    Corvilain B
    Rev Med Brux; 1997 Feb; 18(1):3-9. PubMed ID: 9132915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of L-carnitine on plasma lipoprotein fatty acids pattern in patients with primary hyperlipoproteinemia.
    Stefanutti C; Vivenzio A; Lucani G; Di Giacomo S; Lucani E
    Clin Ter; 1998; 149(2):115-9. PubMed ID: 9780475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.